These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 36001445)

  • 21. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015).
    Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK
    Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of Changes to the Clinical and Laboratory Standards Institute
    Humphries R; Bobenchik AM; Hindler JA; Schuetz AN
    J Clin Microbiol; 2021 Nov; 59(12):e0021321. PubMed ID: 34550809
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories.
    Humphries RM; Abbott AN; Hindler JA
    J Clin Microbiol; 2019 Jun; 57(6):. PubMed ID: 30971460
    [TBL] [Abstract][Full Text] [Related]  

  • 24. India-discovered levonadifloxacin & alalevonadifloxacin: A review on susceptibility testing methods, CLSI quality control and breakpoints along with a brief account of their emerging therapeutic profile as a novel standard-of-care.
    Veeraraghavan B; Bakthavatchalam YD; Manesh A; Lal B; Swaminathan S; Ansari A; Subbareddy K; Rangappa P; Choudhuri AH; Nagvekar V; Mehta Y; Appalaraju B; Baveja S; Baliga S; Shenoy S; Bhardwaj R; Kongre V; Dattatraya GS; Verma B; Mukherjee DN; Gupta S; Shanmugam P; Iravane J; Mishra SR; Barman P; Chopra S; Hariharan M; Surpam R; Pratap R; Turbadkar D; Taklikar S;
    Indian J Med Microbiol; 2023; 41():71-80. PubMed ID: 36509611
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Impact of the Revised 2019 CLSI Levofloxacin Breakpoints in Patients with
    Huang HY; Wang CF; Lu PL; Tseng SP; Wang YL; Chen TC; Chang K; Tu HP; Lin SY
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782006
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surveillance of Fluoroquinolone Resistance in Wisconsin: Geographic Variation and Impact of Revised CLSI Breakpoints.
    Lazzerini G; Lavey SC; Fox BC; Munson E
    Clin Med Res; 2022 Jun; 20(2):81-88. PubMed ID: 35086853
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical implications of revised piperacillin-tazobactam breakpoints in CLSI M-100 S32.
    Dash D; Rai S
    Indian J Med Microbiol; 2023; 42():108-109. PubMed ID: 36241530
    [No Abstract]   [Full Text] [Related]  

  • 28. In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020.
    Karlowsky JA; Lob SH; Siddiqui F; Pavia J; DeRyke CA; Young K; Motyl MR; Sahm DF
    Braz J Infect Dis; 2023; 27(3):102775. PubMed ID: 37169345
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale for a Neisseria gonorrhoeae Susceptible-only Interpretive Breakpoint for Azithromycin.
    Kersh EN; Allen V; Ransom E; Schmerer M; Cyr S; Workowski K; Weinstock H; Patel J; Ferraro MJ
    Clin Infect Dis; 2020 Feb; 70(5):798-804. PubMed ID: 30963175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
    Mushtaq S; Garello P; Vickers A; Woodford N; Livermore DM
    Int J Antimicrob Agents; 2021 May; 57(5):106318. PubMed ID: 33716176
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections.
    Johnson DM; Biedenbach DJ; Jones RN
    Diagn Microbiol Infect Dis; 2002 May; 43(1):49-60. PubMed ID: 12052629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The reliability of using impenem, meropenem, cefoperazone-sulbactam and piperacillin-tazobactam to treat nosocomial Gram-negative bacterial infections with Monte Carlo simulation].
    Xiao YH; Hu YJ
    Zhonghua Nei Ke Za Zhi; 2017 Aug; 56(8):595-600. PubMed ID: 28789493
    [No Abstract]   [Full Text] [Related]  

  • 33. Cephalexin susceptibility breakpoint for veterinary isolates: Clinical Laboratory Standards Institute revision.
    Papich MG; Lindeman C
    J Vet Diagn Invest; 2018 Jan; 30(1):113-120. PubMed ID: 29145786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Letter responding to performance of updated
    Patel JB; Duncan E; Cullen S
    J Clin Microbiol; 2023 Nov; 61(11):e0049723. PubMed ID: 37823655
    [No Abstract]   [Full Text] [Related]  

  • 35. Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers.
    Sader HS; Mendes RE; Kimbrough JH; Kantro V; Castanheira M
    Open Forum Infect Dis; 2023 Feb; 10(2):ofad058. PubMed ID: 36861086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in South African hospitals (SMART Study 2004-2009): impact of the new carbapenem breakpoints.
    Brink AJ; Botha RF; Poswa X; Senekal M; Badal RE; Grolman DC; Richards GA; Feldman C; Boffard KD; Veller M; Joubert I; Pretorius J
    Surg Infect (Larchmt); 2012 Feb; 13(1):43-9. PubMed ID: 22220506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Don't Get Wound Up: Revised Fluoroquinolone Breakpoints for Enterobacteriaceae and Pseudomonas aeruginosa.
    Van TT; Minejima E; Chiu CA; Butler-Wu SM
    J Clin Microbiol; 2019 Jul; 57(7):. PubMed ID: 31043468
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015-2018.
    Pfaller MA; Shortridge D; Harris KA; Garrison MW; DeRyke CA; DePestel DD; Moise PA; Sader HS
    Int J Infect Dis; 2021 Nov; 112():321-326. PubMed ID: 34597763
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of tazobactam-based combinations for the management of infections due to extended-spectrum β-lactamase-producing Enterobacterales: Insights from the Society of Infectious Diseases Pharmacists.
    Monogue ML; Heil EL; Aitken SL; Pogue JM
    Pharmacotherapy; 2021 Oct; 41(10):864-880. PubMed ID: 34689349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulation.
    Frei CR; Wiederhold NP; Burgess DS
    J Antimicrob Chemother; 2008 Mar; 61(3):621-8. PubMed ID: 18252694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.